A First in Human, Dose Escalation Study to Evaluate the Safety and Tolerability of BBP-671 in Healthy Volunteers and Patients With Propionic Acidemia or Methylmalonic Acidemia
A First-in-human, Randomized, Placebo-controlled, Single and Multiple Ascending Dose Escalation to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BBP-671 in Healthy Subjects and In Patients With Propionic Acidemia or Methylmalonic Acidemia
Sponsor: CoA Therapeutics, Inc., a BridgeBio company
Terminated
Slow recruitment
Other Healthy Volunteers trials with similar outcome
Listed as NCT04836494, this PHASE1 trial focuses on Healthy Volunteers and Methylmalonic Acidemia and remains terminated or withdrawn. Sponsored by CoA Therapeutics, Inc., a BridgeBio company, it has been updated 8 times since 2021, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
Jan 2024 — Jul 2024 [monthly]
Terminated PHASE1
Status: Recruiting → Terminated
-
Feb 2023 — Jan 2024 [monthly]
Recruiting PHASE1
-
Nov 2022 — Feb 2023 [monthly]
Recruiting PHASE1
▶ Show 3 earlier versions
-
May 2022 — Nov 2022 [monthly]
Recruiting PHASE1
-
Oct 2021 — May 2022 [monthly]
Recruiting PHASE1
-
May 2021 — Oct 2021 [monthly]
Recruiting PHASE1
First recorded
Mar 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- CoA Therapeutics, Inc., a BridgeBio company
For direct contact, visit the study record on ClinicalTrials.gov .